KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Shares Outstanding (Weighted Average) (2016 - 2025)

Edwards Lifesciences (EW) has 15 years of Shares Outstanding (Weighted Average) data on record, last reported at $584.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 2.16% year-over-year to $584.8 million; the TTM value through Dec 2025 reached $584.8 million, down 2.16%, while the annual FY2025 figure was $584.8 million, 2.16% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $584.8 million in Q4 2025 per EW's latest filing, roughly flat from $584.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $623.3 million in Q4 2021 and bottomed at $584.7 million in Q3 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $607.4 million, with a median of $607.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 0.14% in 2021, then fell 2.6% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $623.3 million in 2021, then fell by 0.69% to $619.0 million in 2022, then dropped by 1.99% to $606.7 million in 2023, then fell by 1.48% to $597.7 million in 2024, then fell by 2.16% to $584.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $584.8 million in Q4 2025, $584.7 million in Q3 2025, and $586.9 million in Q2 2025.